{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T11:44:12Z","timestamp":1792496652180,"version":"4.5.0"},"reference-count":60,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Child and Adolescent Psychopharmacology"],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Down syndrome (DS) is a major genetic cause of intellectual disability. In an animal model of DS, fluoxetine was shown to restore brain architecture and cognitive performance, acting primarily on the hippocampus, with effects persisting after treatment discontinuation. In this translational study, we assessed the safety and tolerability of fluoxetine at the standard labeled dose and explored selected efficacy endpoints to inform future clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The study was approved as a phase I, open-label study. Participants with full trisomy 21 received fluoxetine (10 mg\/day) for 6 months, followed by a 6-month observation period. The primary endpoint, safety and tolerability, was evaluated through clinical examinations, biochemistry, plasma fluoxetine and norfluoxetine levels, electroencephalography, and electrocardiography at multiple time-points. As a secondary efficacy endpoint, we selected a set of cognitive tests to explore hippocampus-dependent functions and adaptive behavior.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Fourteen children with DS (8.1 \u00b1 1.24 years; range 6\u201310) were enrolled, and 12 completed the 12-month study. No serious or severe adverse events (AEs) occurred. All AEs resolved without sequelae. Short-term terminal insomnia was observed in two patients. Neuropsychological assessments revealed improvements in visuospatial processing tasks during the study. Analysis of adaptive behavior suggested enhanced expression skills.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>These findings indicate that fluoxetine is safe in children with DS. The association with terminal insomnia warrants specific investigation in future trials and strategies to optimize tolerability are discussed. Efficacy analyses highlight the visuospatial processing domain as potentially responsive to treatment, supporting further research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10445463261458603","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T07:38:32Z","timestamp":1780990712000},"page":"432-442","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of Fluoxetine on Cognitive Functioning in Children with Down Syndrome: A Prospective Open-Label Exploratory Study of Safety and Efficacy"],"prefix":"10.1177","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2725-437X","authenticated-orcid":false,"given":"Iris","family":"Scala","sequence":"first","affiliation":[{"name":"Department of Maternal and Child Health, Federico II University Hospital, Naples, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Bravaccio","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, Federico II University, Naples, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Marino","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, Federico II University, Naples, Italy."},{"name":"Cognitive Psychotherapy School of Naples, Naples, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriana","family":"Scicolone","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, Federico II University, Naples, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Maffettone","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, Federico II University, Naples, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pia","family":"Riccio","sequence":"additional","affiliation":[{"name":"Department of Maternal and Child Health, Federico II University Hospital, Naples, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Terrone","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, Federico II University, Naples, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Cattaneo","sequence":"additional","affiliation":[{"name":"Unit of Clinical Pathology, ASST Fatebenefratelli Sacco, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Clementi","sequence":"additional","affiliation":[{"name":"\u201cLuigi Sacco\u201d University Hospital, Universit\u00e0 degli Studi di Milano, Milan, Italy."},{"name":"Scientific Institute IRCCS Eugenio Medea, Bosisio Parini, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Bartesaghi","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Strisciuglio","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, Federico II University, Naples, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"e_1_3_5_2_1","unstructured":"Agenzia Italiana del Farmaco. Prozac 20 mg\/5 mL soluzione orale (fluoxetina): Riassunto delle caratteristiche del prodotto. Agenzia Italiana del Farmaco; 2013. Available from: https:\/\/www.aifa.gov.it\/ [Last accessed: February20 2026]."},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S32767"},{"issue":"6","key":"e_1_3_5_4_1","first-page":"353","article-title":"Estudio abierto con fluoxetina en ni\u00f1os con autismo [Open study of fluoxetine in children with autism]","volume":"28","author":"Alcam\u00ed Pertejo M","year":"2000","unstructured":"Alcam\u00ed Pertejo M, , Peral Guerra M, , Gilaberte I. Estudio abierto con fluoxetina en ni\u00f1os con autismo [Open study of fluoxetine in children with autism]. Actas Esp Psiquiatr 2000;28(6):353\u2013356.","journal-title":"Actas Esp Psiquiatr"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0534-10.2010"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2012.04.024"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2013.5"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2009.75"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jar.12438"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511581779"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3148.2011.00676.x"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ridd.2014.07.014"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2022.06.011"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2012.10.020"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-016-1370-9"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00369-0"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)30034-5"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199410020-00001"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/genes15040452"},{"key":"e_1_3_5_20_1","first-page":"103","article-title":"Pharmacological approaches to improving cognitive function in Down syndrome: Current status and considerations","volume":"9","author":"Gardiner KJ","year":"2015","unstructured":"Gardiner KJ. Pharmacological approaches to improving cognitive function in Down syndrome: Current status and considerations. Drug Des Devel Ther 2015;9:103\u2013125.","journal-title":"Drug Des Devel Ther"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/089198879701000302"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200107000-00011"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2788.2005.00643.x"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s11689-022-09418-0"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/10445463251379822"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-3639.2012.00624.x"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awt340"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61676-0"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-116492"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300627"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2013.01.005"},{"key":"e_1_3_5_32_1","volume-title":"K-SADS-PL, intervista diagnostica per la valutazione dei disturbi psicopatologici in bambini e adolescenti","author":"Kaufman J","year":"2004","unstructured":"Kaufman J, , Birmaher B, , Brent D, et al. K-SADS-PL, intervista diagnostica per la valutazione dei disturbi psicopatologici in bambini e adolescenti. Erickson: Trento; 2004."},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.33730"},{"key":"e_1_3_5_34_1","volume-title":"NEPSY-II: A Developmental Neuropsychological Assessment","author":"Korkman M","year":"2007","unstructured":"Korkman M, , Kirk U, , Kemp S. NEPSY-II: A Developmental Neuropsychological Assessment, 2nd ed. Italian adaptation: Urgesi C, Campanella F, Fabbro F. NEPSY-II. Contributo alla taratura italiana; 2011. Giunti O.S.: Firenze; 2007.","edition":"2"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c01888"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnbeh.2015.00300"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2024.105679"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1291242"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abq4515"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13052-019-0672-4"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-019-0597-8"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005053-199209000-00015"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-05825-4"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/1467-8624.00522"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ridd.2013.11.016"},{"key":"e_1_3_5_46_1","first-page":"67","volume-title":"Int Rev Res Dev Disabil","author":"Pulina F","year":"2019","unstructured":"Pulina F, , Vianello R, , Lanfranchi S. Cognitive profiles in individuals with Down syndrome. In: Int Rev Res Dev Disabil. (Lanfranchi S., ed.) Elsevier Academic Press: London; 2019; pp. 67\u201392."},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.0983"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-108X(199801)23:1<107::AID-EAT15>3.0.CO;2-Z"},{"key":"e_1_3_5_49_1","volume-title":"Leiter International Performance Scale-Revised","author":"Roid GH","year":"2002","unstructured":"Roid GH, , Miller LJ. Leiter International Performance Scale-Revised. Organizzazioni Speciali: Florence; 2002."},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-020-00296-2"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.3390\/antiox10030469"},{"key":"e_1_3_5_52_1","volume-title":"Vineland Adaptive Behavior Scales\u2013Second Edition (Vineland II)\u2013Survey Interview Form","author":"Sparrow SS","year":"2016","unstructured":"Sparrow SS, , Cicchetti DV, , Balla DA. Vineland Adaptive Behavior Scales\u2013Second Edition (Vineland II)\u2013Survey Interview Form. Giunti O.S.: Florence; 2016."},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.37650"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2022.903729"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2014.12.005"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnbeh.2015.00265"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061689"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2024.0124"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.13m08562"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70874"},{"key":"e_1_3_5_61_1","volume-title":"WISC-IV: Wechsler Intelligence Scale for Children\u2013Fourth Edition","author":"Wechsler D","year":"2012","unstructured":"Wechsler D. WISC-IV: Wechsler Intelligence Scale for Children\u2013Fourth Edition. Giunti O.S.: Florence; 2012."}],"container-title":["Journal of Child and Adolescent Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10445463261458603","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10445463261458603","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10445463261458603","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T11:33:49Z","timestamp":1792496029000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10445463261458603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":60,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,9,1]]}},"alternative-id":["10.1177\/10445463261458603"],"URL":"https:\/\/doi.org\/10.1177\/10445463261458603","relation":{},"ISSN":["1044-5463","1557-8992"],"issn-type":[{"value":"1044-5463","type":"print"},{"value":"1557-8992","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]}}}